Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
V125545-10mg | 10mg | In stock | $53.90 | |
V125545-50mg | 50mg | In stock | $118.90 | |
V125545-250mg | 250mg | In stock | $535.90 | |
V125545-1g | 1g | In stock | $706.90 |
Synonyms | VORTIOXETINE|508233-74-7|1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine|Lu AA21004|1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine|Vortioxetine free base|vortioxetina|vortioxetinum|1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine|UNII-3O2K1S3WQV| |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST, ANTAGONIST, INHIBITOR |
Mechanism of action | Agonist of 5-HT 1A receptor;Agonist of 5-HT 1B receptor;Antagonist of 5-HT 1D receptor;Antagonist of 5-HT 2A receptor;Antagonist of 5-HT 3A;Antagonist of 5-HT 5A receptor;Antagonist of 5-HT 6 receptor;Antagonist of 5-HT 7 receptor;Inhibitor of SERT |
Product Description | Vortioxetine (Lu AA21004) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. IC50 Value: 15nM (5-HT1A); 33nM (5-HT1B); 3.7nM(5-HT3A); 19nM (5-HT7); 1.6 nM(SERT) Target: 5-HT receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488196483 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488196483 |
IUPAC Name | 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine |
INCHI | InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3 |
InChi Key | YQNWZWMKLDQSAC-UHFFFAOYSA-N |
Canonical SMILES | CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |
Isomeric SMILES | CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |
Alternate CAS | 508233-74-7 |
PubChem CID | 9966051 |
MeSH Entry Terms | 1-(2-(2,4-dimethylphenylsulfanyl)phenyl)piperazine;brintellix;Lu AA21004;Lu-AA21004;LuAA21004;vortioxetine;vortioxetine hydrobromide |
Molecular Weight | 298.45 |
PubChem CID | 9966051 |
---|---|
Wikipedia | Vortioxetine |
CAS Registry No. | 508233-74-7 |
ChEMBL Ligand | CHEMBL2104993 |
PEP | vortioxetine |
DrugCentral Ligand | 4806 |
GPCRdb Ligand | vortioxetine |
PubChem SID | 488196483 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L1713086 | Certificate of Analysis | May 10, 2023 | V125545 |
C2304106 | Certificate of Analysis | Feb 13, 2023 | V125545 |
C2304107 | Certificate of Analysis | Feb 13, 2023 | V125545 |
C2304108 | Certificate of Analysis | Feb 13, 2023 | V125545 |
C2304111 | Certificate of Analysis | Feb 13, 2023 | V125545 |
E2315528 | Certificate of Analysis | Feb 13, 2023 | V125545 |
Solubility | ≥ 14.9 mg/mL in DMSO;≥ 4.31 mg/mL in EtOH with ultrasonic;insoluble in H2O |
---|
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H373:Causes damage to organs through prolonged or repeated exposure H361:Suspected of damaging fertility or the unborn child H371:May cause damage to organs |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. P308+P316:IF exposed or concerned: Get emergency medical help immediately. P319:Get medical help if you feel unwell. |
1. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al.. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.. J Med Chem, 54 (9): (3206-21). [PMID:21486038] |
2. Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. (2018) Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages.. Br J Pharmacol, 175 (1): (113-124). [PMID:29057467] |